These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1086 related articles for article (PubMed ID: 25559344)

  • 1. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance.
    Fang S; Suh JM; Reilly SM; Yu E; Osborn O; Lackey D; Yoshihara E; Perino A; Jacinto S; Lukasheva Y; Atkins AR; Khvat A; Schnabl B; Yu RT; Brenner DA; Coulter S; Liddle C; Schoonjans K; Olefsky JM; Saltiel AR; Downes M; Evans RM
    Nat Med; 2015 Feb; 21(2):159-65. PubMed ID: 25559344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity: Gut-specific FXR agonism.
    Osório J
    Nat Rev Endocrinol; 2015 Mar; 11(3):131. PubMed ID: 25623122
    [No Abstract]   [Full Text] [Related]  

  • 3. Obesity and diabetes: FXR and JAK step up to BAT.
    Cully M
    Nat Rev Drug Discov; 2015 Feb; 14(2):91. PubMed ID: 25633788
    [No Abstract]   [Full Text] [Related]  

  • 4. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
    Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
    Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
    Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
    Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
    Zhou M; Luo J; Chen M; Yang H; Learned RM; DePaoli AM; Tian H; Ling L
    J Hepatol; 2017 Jun; 66(6):1182-1192. PubMed ID: 28189755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiota-induced obesity requires farnesoid X receptor.
    Parséus A; Sommer N; Sommer F; Caesar R; Molinaro A; Ståhlman M; Greiner TU; Perkins R; Bäckhed F
    Gut; 2017 Mar; 66(3):429-437. PubMed ID: 26740296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice.
    Stroeve JH; Brufau G; Stellaard F; Gonzalez FJ; Staels B; Kuipers F
    Lab Invest; 2010 Oct; 90(10):1457-67. PubMed ID: 20531290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
    Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
    Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation.
    Rau M; Stieger B; Monte MJ; Schmitt J; Jahn D; Frey-Wagner I; Raselli T; Marin JJ; Müllhaupt B; Rogler G; Geier A
    Inflamm Bowel Dis; 2016 Oct; 22(10):2382-9. PubMed ID: 27580383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice.
    Ikpa PT; Doktorova M; Meijsen KF; Nieuwenhuijze NDA; Verkade HJ; Jonker JW; de Jonge HR; Bijvelds MJC
    Cell Mol Gastroenterol Hepatol; 2020; 9(1):47-60. PubMed ID: 31470114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity.
    Prawitt J; Abdelkarim M; Stroeve JH; Popescu I; Duez H; Velagapudi VR; Dumont J; Bouchaert E; van Dijk TH; Lucas A; Dorchies E; Daoudi M; Lestavel S; Gonzalez FJ; Oresic M; Cariou B; Kuipers F; Caron S; Staels B
    Diabetes; 2011 Jul; 60(7):1861-71. PubMed ID: 21593203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.
    Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A
    Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
    Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
    Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.
    Liu Y; Chen K; Li F; Gu Z; Liu Q; He L; Shao T; Song Q; Zhu F; Zhang L; Jiang M; Zhou Y; Barve S; Zhang X; McClain CJ; Feng W
    Hepatology; 2020 Jun; 71(6):2050-2066. PubMed ID: 31571251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations.
    Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol.
    Bertolini A; van de Peppel IP; Doktorova-Demmin M; Bodewes FAJA; de Jonge H; Bijvelds M; Verkade HJ; Jonker JW
    Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G404-G411. PubMed ID: 30653340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice.
    de Boer JF; Schonewille M; Boesjes M; Wolters H; Bloks VW; Bos T; van Dijk TH; Jurdzinski A; Boverhof R; Wolters JC; Kuivenhoven JA; van Deursen JM; Oude Elferink RPJ; Moschetta A; Kremoser C; Verkade HJ; Kuipers F; Groen AK
    Gastroenterology; 2017 Apr; 152(5):1126-1138.e6. PubMed ID: 28065787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure.
    Watanabe M; Horai Y; Houten SM; Morimoto K; Sugizaki T; Arita E; Mataki C; Sato H; Tanigawara Y; Schoonjans K; Itoh H; Auwerx J
    J Biol Chem; 2011 Jul; 286(30):26913-20. PubMed ID: 21632533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21.
    Kim T; Nason S; Holleman C; Pepin M; Wilson L; Berryhill TF; Wende AR; Steele C; Young ME; Barnes S; Drucker DJ; Finan B; DiMarchi R; Perez-Tilve D; Tschöp M; Habegger KM
    Diabetes; 2018 Sep; 67(9):1773-1782. PubMed ID: 29925501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.